Skip to main content
Premium Trial:

Request an Annual Quote

Astex Joins Cancer Drug Discovery Collaboration

NEW YORK, March 22 (GenomeWeb News) - Astex Technology has formed an exclusive collaboration with The Wellcome Trust, the Institute of Cancer Research, and Cancer Research Technology to discover novel drugs against the cancer target BRAF, the partners said today.

 

The Wellcome Trust, the Instituteof Cancer Research, and Cancer Research Technology began a partnership focusing on BRAF last year, and have now been joined by Astex, which will contribute its fragment-based drug discovery expertise.

 

"There is excellent synergy between the collaborating parties," Ted Bianco, director of technology transfer at The Wellcome Trust, said in a statement. "Astex's structure-based approach to drug discovery is highly complementary to the cancer therapeutic resources of the other parties."

 

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.